SE0202598D0 - Alpha-7 Nicotinic receptor agonists and statins in combination - Google Patents
Alpha-7 Nicotinic receptor agonists and statins in combinationInfo
- Publication number
- SE0202598D0 SE0202598D0 SE0202598A SE0202598A SE0202598D0 SE 0202598 D0 SE0202598 D0 SE 0202598D0 SE 0202598 A SE0202598 A SE 0202598A SE 0202598 A SE0202598 A SE 0202598A SE 0202598 D0 SE0202598 D0 SE 0202598D0
- Authority
- SE
- Sweden
- Prior art keywords
- statins
- alpha
- combination
- receptor agonists
- nicotinic receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202598A SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Alpha-7 Nicotinic receptor agonists and statins in combination |
AU2003256203A AU2003256203A1 (en) | 2002-09-02 | 2003-09-01 | Alpha-7 nicotinic receptor agonists and statins in combination |
JP2004532517A JP2006505530A (ja) | 2002-09-02 | 2003-09-01 | アルファ−7ニコチン受容体作用剤およびスタチンの組み合わせ |
ES03791540T ES2283860T3 (es) | 2002-09-02 | 2003-09-01 | Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados. |
DK03791540T DK1545537T3 (da) | 2002-09-02 | 2003-09-01 | Alfa-7-nikotinreceptoragonister og statiner i kombination |
DE60313004T DE60313004T2 (de) | 2002-09-02 | 2003-09-01 | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination |
PT03791540T PT1545537E (pt) | 2002-09-02 | 2003-09-01 | Agonistas do receptor alfa-7 nicotínico e estatinas em combinação |
SI200330803T SI1545537T1 (sl) | 2002-09-02 | 2003-09-01 | Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji |
PCT/SE2003/001352 WO2004019947A1 (en) | 2002-09-02 | 2003-09-01 | Alpha-7 nicotinic receptor agonists and statins in combination |
US10/525,783 US20050256146A1 (en) | 2002-09-02 | 2003-09-01 | Alpha-7 nicotinic receptor agonists and stains in combination |
EP03791540A EP1545537B9 (en) | 2002-09-02 | 2003-09-01 | Alpha-7 nicotinic receptor agonists and statins in combination |
AT03791540T ATE358485T1 (de) | 2002-09-02 | 2003-09-01 | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination |
HK05109104A HK1077193A1 (en) | 2002-09-02 | 2005-10-14 | Alpha-7 nicotinic receptor agonists and statins incombination |
US12/186,915 US20090192180A1 (en) | 2002-09-02 | 2008-08-06 | Alpha-7 Nicotinic Receptor Agonists and Statins In Combination |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202598A SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Alpha-7 Nicotinic receptor agonists and statins in combination |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0202598D0 true SE0202598D0 (sv) | 2002-09-02 |
Family
ID=20288874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0202598A SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Alpha-7 Nicotinic receptor agonists and statins in combination |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050256146A1 (sv) |
EP (1) | EP1545537B9 (sv) |
JP (1) | JP2006505530A (sv) |
AT (1) | ATE358485T1 (sv) |
AU (1) | AU2003256203A1 (sv) |
DE (1) | DE60313004T2 (sv) |
DK (1) | DK1545537T3 (sv) |
ES (1) | ES2283860T3 (sv) |
HK (1) | HK1077193A1 (sv) |
PT (1) | PT1545537E (sv) |
SE (1) | SE0202598D0 (sv) |
SI (1) | SI1545537T1 (sv) |
WO (1) | WO2004019947A1 (sv) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
UA105903C2 (uk) | 2008-06-20 | 2014-07-10 | Астразенека Аб | Похідні дибензотіазепіну та їх застосування |
FR2958850B1 (fr) * | 2010-04-14 | 2012-07-06 | Centre Nat Rech Scient | Medicaments pour la prevention ou le traitement des addictions aux drogues |
NO3029039T3 (sv) | 2010-05-17 | 2018-01-20 | ||
EP2593447B1 (de) * | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel |
EP3673906A1 (en) * | 2011-03-18 | 2020-07-01 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
JPWO2013161871A1 (ja) * | 2012-04-25 | 2015-12-24 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
EP3666272A1 (en) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
EP3010900B1 (en) | 2013-06-21 | 2018-01-03 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
CN103923105B (zh) * | 2014-04-17 | 2016-08-24 | 北京大学 | 2-中氮茚甲酰胺类化合物及其制备和用途 |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
EP3806956A4 (en) * | 2018-06-13 | 2022-08-10 | Zachriel Neurosciences, Llc | METHODS AND DOSAGE REGIMES FOR PREVENTING OR DELAYING THE ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9701292A (es) * | 1994-08-24 | 1997-05-31 | Astra Ab | Compuestos espiro-azabiciclicos utiles en la terapia. |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
SE9903996D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
US6500840B2 (en) * | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
US20050222122A1 (en) * | 2002-04-02 | 2005-10-06 | Sean Lilienfeld | Statin therapy for enhancing cognitive maintenance |
PL377777A1 (pl) * | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
CN103724343A (zh) * | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
-
2002
- 2002-09-02 SE SE0202598A patent/SE0202598D0/sv unknown
-
2003
- 2003-09-01 DK DK03791540T patent/DK1545537T3/da active
- 2003-09-01 AT AT03791540T patent/ATE358485T1/de not_active IP Right Cessation
- 2003-09-01 WO PCT/SE2003/001352 patent/WO2004019947A1/en active IP Right Grant
- 2003-09-01 ES ES03791540T patent/ES2283860T3/es not_active Expired - Lifetime
- 2003-09-01 PT PT03791540T patent/PT1545537E/pt unknown
- 2003-09-01 AU AU2003256203A patent/AU2003256203A1/en not_active Abandoned
- 2003-09-01 US US10/525,783 patent/US20050256146A1/en not_active Abandoned
- 2003-09-01 JP JP2004532517A patent/JP2006505530A/ja not_active Abandoned
- 2003-09-01 EP EP03791540A patent/EP1545537B9/en not_active Expired - Lifetime
- 2003-09-01 DE DE60313004T patent/DE60313004T2/de not_active Expired - Fee Related
- 2003-09-01 SI SI200330803T patent/SI1545537T1/sl unknown
-
2005
- 2005-10-14 HK HK05109104A patent/HK1077193A1/xx not_active IP Right Cessation
-
2008
- 2008-08-06 US US12/186,915 patent/US20090192180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE358485T1 (de) | 2007-04-15 |
AU2003256203A1 (en) | 2004-03-19 |
EP1545537B9 (en) | 2008-08-20 |
DK1545537T3 (da) | 2007-07-02 |
PT1545537E (pt) | 2007-06-20 |
US20050256146A1 (en) | 2005-11-17 |
JP2006505530A (ja) | 2006-02-16 |
US20090192180A1 (en) | 2009-07-30 |
EP1545537A1 (en) | 2005-06-29 |
WO2004019947A1 (en) | 2004-03-11 |
SI1545537T1 (sl) | 2007-08-31 |
DE60313004D1 (de) | 2007-05-16 |
HK1077193A1 (en) | 2006-02-10 |
ES2283860T3 (es) | 2007-11-01 |
EP1545537B1 (en) | 2007-04-04 |
DE60313004T2 (de) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0202598D0 (sv) | Alpha-7 Nicotinic receptor agonists and statins in combination | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
IL251185A0 (en) | mek inhibitors and methods of using them | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
HUS1700003I1 (hu) | Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
GEP20094845B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
CA2514473A1 (en) | Fused bicyclic nitrogen-containing heterocycles | |
BR0313233A (pt) | Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica | |
ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
MY147393A (en) | Administration of dipeptidyl peptidase inhibitors | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
SG130189A1 (en) | Substituted indole-o-glucosides | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
UA87991C2 (en) | Substituted indole-o-glucosides | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. |